Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study
Pfizer $PFE and its partner Merck KGaA have run into a dead end in their race to expand the market for their PD-L1 checkpoint Bavencio (avelumab). Researchers today conceded that the checkpoint — one of 5 now scrambling to expand their market turf in the mega-blockbuster global oncology business — failed to significantly improve overall survival for advanced gastric cancer patients compared to best standard of care.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.